|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Buendia MA and Neuveut C: Hepatocellular
carcinoma. Cold Spring Harb Perspect Med. 5:a0214442015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Radeleff BA, Stampfl U, Sommer CM,
Bellemann N, Hoffmann K, Ganten T, Ehehalt R and Kauczor HU:
Transarterial ablation of hepatocellular carcinoma. Status and
developments. Radiologe. 52:44–55. 2012.In German. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lencioni R and Crocetti L: Local-regional
treatment of hepatocellular carcinoma. Radiology. 262:43–58. 2012.
View Article : Google Scholar
|
|
5
|
de Lope CR, Tremosini S, Forner A, Reig M
and Bruix J: Management of HCC. J Hepatol. 56(Suppl 1): S75–S87.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schmierer B and Hill CS: TGFbeta-SMAD
signal transduction: Molecular specificity and functional
flexibility. Nat Rev Mol Cell Biol. 8:970–982. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Akhurst RJ and Hata A: Targeting the TGFβ
signalling pathway in disease. Nat Rev Drug Discov. 11:790–811.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang S, Sun WY, Wu JJ and Wei W: TGF-β
signaling pathway as a pharmacological target in liver diseases.
Pharmacol Res. 85:15–22. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Derynck R and Zhang YE: Smad-dependent and
Smad-independent pathways in TGF-beta family signalling. Nature.
425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
López-Casillas F, Cheifetz S, Doody J,
Andres JL, Lane WS and Massagué J: Structure and expression of the
membrane proteoglycan betaglycan, a component of the TGF-beta
receptor system. Cell. 67:785–795. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang XF, Lin HY, Ng-Eaton E, Downward J,
Lodish HF and Weinberg RA: Expression cloning and characterization
of the TGF-beta type III receptor. Cell. 67:797–805. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shi Y and Massagué J: Mechanisms of
TGF-beta signaling from cell membrane to the nucleus. Cell.
113:685–700. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thatcher JD: The TGF-beta signal
transduction pathway. Sci Signal. 3:tr42010.PubMed/NCBI
|
|
14
|
Li D, Xu D, Lu Z, Dong X and Wang X:
Overexpression of transforming growth factor type III receptor
restores TGF-β1 sensitivity in human tongue squamous cell carcinoma
cells. Biosci Rep. 35:352015. View Article : Google Scholar
|
|
15
|
Tazat K, Hector-Greene M, Blobe GC and
Henis YI: TβRIII independently binds type I and type II TGF-β
receptors to inhibit TGF-β signaling. Mol Biol Cell. 26:3535–3545.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong M, How T, Kirkbride KC, Gordon KJ,
Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR and Blobe GC: The
type III TGF-beta receptor suppresses breast cancer progression. J
Clin Invest. 117:206–217. 2007. View
Article : Google Scholar
|
|
17
|
Turley RS, Finger EC, Hempel N, How T,
Fields TA and Blobe GC: The type III transforming growth
factor-beta receptor as a novel tumor suppressor gene in prostate
cancer. Cancer Res. 67:1090–1098. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Finger EC, Turley RS, Dong M, How T,
Fields TA and Blobe GC: TbetaRIII suppresses non-small cell lung
cancer invasiveness and tumorigenicity. Carcinogenesis. 29:528–535.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hempel N, How T, Dong M, Murphy SK, Fields
TA and Blobe GC: Loss of betaglycan expression in ovarian cancer:
Role in motility and invasion. Cancer Res. 67:5231–5238. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen C, Wang XF and Sun L: Expression of
transforming growth factor beta (TGFbeta) type III receptor
restores autocrine TGFbeta1 activity in human breast cancer MCF-7
cells. J Biol Chem. 272:12862–12867. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun L and Chen C: Expression of
transforming growth factor beta type III receptor suppresses
tumorigenicity of human breast cancer MDA-MB-231 cells. J Biol
Chem. 272:25367–25372. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Millan FA, Denhez F, Kondaiah P and
Akhurst RJ: Embryonic gene expression patterns of TGF beta 1, beta
2 and beta 3 suggest different developmental functions in vivo.
Development. 111:131–143. 1991.PubMed/NCBI
|
|
23
|
Derynck R and Akhurst RJ: Differentiation
plasticity regulated by TGF-beta family proteins in development and
disease. Nat Cell Biol. 9:1000–1004. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang AL, Liu SG, Qi WJ, Zhao YF, Li YM,
Lei B, Sheng WJ and Shen H: TGF-β1 protein expression in non-small
cell lung cancers is correlated with prognosis. Asian Pac J Cancer
Prev. 15:8143–8147. 2014. View Article : Google Scholar
|
|
25
|
Chen K, Wei H, Ling S and Yi C: Expression
and significance of transforming growth factor-β1 in epithelial
ovarian cancer and its extracellular matrix. Oncol Lett.
8:2171–2174. 2014.PubMed/NCBI
|
|
26
|
Ji GZ, Wang XH, Miao L, Liu Z, Zhang P,
Zhang FM and Yang JB: Role of transforming growth factor-beta1-smad
signal transduction pathway in patients with hepatocellular
carcinoma. World J Gastroenterol. 12:644–648. 2006.PubMed/NCBI
|
|
27
|
Abou-Shady M, Baer HU, Friess H, Berberat
P, Zimmermann A, Graber H, Gold LI, Korc M and Büchler MW:
Transforming growth factor betas and their signaling receptors in
human hepatocellular carcinoma. Am J Surg. 177:209–215. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tsai JF, Chuang LY, Jeng JE, Yang ML,
Chang WY, Hsieh MY, Lin ZY and Tsai JH: Clinical relevance of
transforming growth factor-beta 1 in the urine of patients with
hepatocellular carcinoma. Medicine. 76:213–226. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hempel N, How T, Cooper SJ, Green TR, Dong
M, Copland JA, Wood CG and Blobe GC: Expression of the type III
TGF-beta receptor is negatively regulated by TGF-beta.
Carcinogenesis. 29:905–912. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang S, Sun WY, Gu YJ and Wei W: The
expression of type III TGF-β receptor in diethylnitrosamine-induced
liver cancer model. Acta Univ Medicinalis Anhui. 50:912–916.
2015.In Chinese.
|
|
31
|
Bae HJ, Eun JW, Noh JH, Kim JK, Jung KH,
Xie HJ, Park WS, Lee JY and Nam SW: Down-regulation of transforming
growth factor β receptor type III in hepatocellular carcinoma is
not directly associated with genetic alterations or loss of
heterozygosity. Oncol Rep. 22:475–480. 2009.PubMed/NCBI
|
|
32
|
Sharifi N, Hurt EM, Kawasaki BT and Farrar
WL: TGFBR3 loss and consequences in prostate cancer. Prostate.
67:301–311. 2007. View Article : Google Scholar
|
|
33
|
You HJ, How T and Blobe GC: The type III
transforming growth factor-beta receptor negatively regulates
nuclear factor kappa B signaling through its interaction with
beta-arrestin2. Carcinogenesis. 30:1281–1287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Criswell TL and Arteaga CL: Modulation of
NFkappaB activity and E-cadherin by the type III transforming
growth factor beta receptor regulates cell growth and motility. J
Biol Chem. 282:32491–32500. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Margulis V, Maity T, Zhang XY, Cooper SJ,
Copland JA and Wood CG: Type III transforming growth factor-beta
(TGF-beta) receptor mediates apoptosis in renal cell carcinoma
independent of the canonical TGF-beta signaling pathway. Clin
Cancer Res. 14:5722–5730. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ahn JY, Park S, Yun YS and Song JY:
Inhibition of type III TGF-β receptor aggravates lung fibrotic
process. Biomed Pharmacother. 64:472–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
